We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Collagen Solutions Plc

23 Apr 2020 12:10



Form 8.3 - Collagen Solutions Plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Rathbone Brothers PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeCollagen Solutions Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure22/04/2020
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:  
InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled:12,354,5512.7845%  
(2) Cash-settled derivatives:     
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:12,354,5512.7845%  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/sale Number of securitiesPrice per unit
N/AN/A N/AN/A

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
    

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:23/04/2020
Contact name:Angela Hepburn – Compliance Department
Telephone number:0151 236 6666

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.


Date   Source Headline
12th Sep 20167:00 amRNSIssue of Equity
24th Aug 201611:26 amRNSResult of AGM
25th Jul 201611:48 amRNSPosting of Annual Report
19th Jul 20167:15 amRNSHardman research: Focused scalable growth
15th Jul 20167:00 amRNSGrant of Options
12th Jul 20165:12 pmRNSDirector/PDMR Shareholding
12th Jul 201611:51 amRNSHolding(s) in Company
11th Jul 20164:15 pmRNSDirector/PDMR Shareholding
11th Jul 20163:16 pmRNSDirector/PDMR Shareholding
11th Jul 20167:00 amRNSFinal Results
13th Jun 20167:00 amRNSNotice of Results Investor Presentation
4th May 20167:00 amRNSDirectorate Change
3rd May 20167:00 amRNSLeadership changes and preliminary FY revenue
27th Apr 20165:34 pmRNSHolding(s) in Company
26th Apr 20168:28 amRNSJoint Venture Agreement in China
19th Apr 20167:00 amRNSSupply of collagen materials to Merck
30th Mar 20169:37 amRNSHolding(s) in Company
23rd Mar 20167:00 amRNSResearch collaboration
26th Feb 20161:02 pmRNSHolding(s) in Company
12th Feb 20167:00 amRNSDeath of adviser
3rd Feb 20167:00 amRNSCollagen Solutions present at The Scotsman
22nd Jan 20165:47 pmRNSHolding(s) in Company
21st Jan 201610:14 amRNSChairman's Share Purchase
20th Jan 20167:00 amRNSTrading Update
14th Jan 20165:29 pmRNSHolding(s) in Company
9th Dec 201511:17 amRNSHolding(s) in Company
9th Dec 20157:00 amRNSHardman Issues Research Report
7th Dec 20157:00 amRNSCollagen Solutions Supply Agreement with BBI
2nd Dec 20153:48 pmRNSDirector/PDMR Shareholding
1st Dec 20157:00 amRNSHalf Yearly Report
20th Nov 20153:20 pmRNSDeath of a Director
18th Nov 20157:00 amRNSAppointment of Chief Business Officer
3rd Nov 20157:00 amRNSNotice of Results
28th Sep 20157:00 amRNSCollagen supply agreement to Yucel Medical
22nd Sep 20157:00 amRNSMedical Research Studentship
16th Sep 20157:00 amRNSSupply Agreement with Histogenics Corporation
14th Sep 20157:00 amRNSAcquisition of a regenerative medicine product
3rd Sep 20157:00 amRNSFDA approval for NovaBone product
28th Aug 201510:11 amRNSAGM Statement
28th Aug 20157:00 amRNSJoins consortium developing new treatments
22nd Jul 20157:00 amRNSPosting of Annual Report & Notice of AGM
15th Jul 201510:09 amRNSHardman & Co issues research on Collagen Solutions
14th Jul 20157:00 amRNSPartnership with UCL and Oxford MEStar Ltd
13th Jul 20157:00 amRNSFinal Results
3rd Jul 20152:11 pmRNSNotice of Results
26th Jun 20157:00 amRNSChange of Adviser
22nd Jun 20157:00 amRNSInnovate UK Grant Award
28th May 20157:00 amRNSNew Patent Granted
17th Apr 20151:53 pmRNSHardman & Co issues research report
14th Apr 20157:00 amRNSUK Investor Show attendance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.